Literature DB >> 24138979

Acute generalized exanthematous pustulosis induced by hydroxychloroquine: first case report in Canada and review of the literature.

Kristy Bailey, Daniel McKee, Judy Wismer, Neil Shear.   

Abstract

BACKGROUND: Acute generalized exanthematous pustulosis (AGEP) is a rare drug eruption presenting with an acute, extensive formation of nonfollicular sterile pustules on an erythematous and edematous base. Typically, the rash is accompanied by fever and leukocytosis, with spontaneous resolution in < 15 days. The incidence of AGEP is estimated at one to five cases per million people per year. Only 18% of these are from nonantibiotics. Hydroxychloroquine (HCQ) is an antimalarial agent that is also used to treat various dermatologic and rheumatologic conditions.
OBJECTIVE: We report the first observation in Canada of a patient with AGEP induced by HCQ. METHODS AND
RESULTS: AGEP was diagnosed in a 48-year-old female who had been taking HCQ for 2 weeks and then developed a diffuse erythematous and edematous pustular eruption. Clinical and pathologic findings were consistent with a diagnosis of AGEP. The patient was treated with steroids and supportive measures. The rash resolved after 18 days and a complicated course in hospital.
CONCLUSION: AGEP is a rare drug eruption, usually to antibiotics. We report the first case in Canada of AGEP as an adverse reaction to HCQ. Clinicians should keep in mind the possibility of this severe skin eruption.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24138979     DOI: 10.2310/7750.2013.12105

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  7 in total

Review 1.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

2.  Successful Treatment of Hydroxychloroquine-Induced Recalcitrant Acute Generalized Exanthematous Pustulosis with Cyclosporine: Case Report and Literature Review.

Authors:  Başak Yalçın; Seray Çakmak; Betül Yıldırım
Journal:  Ann Dermatol       Date:  2015-07-29       Impact factor: 1.444

3.  Hydroxychloroquine-induced acute generalized exanthematous pustulosis with positive patch-testing.

Authors:  Ons Charfi; Sarrah Kastalli; Rym Sahnoun; Ghozlane Lakhoua
Journal:  Indian J Pharmacol       Date:  2015 Nov-Dec       Impact factor: 1.200

4.  Pustular drug eruption due to Panax notoginseng saponins.

Authors:  ZhiQiang Yin; LiWen Ma; JiaLi Xu; JiPing Xia; Dan Luo
Journal:  Drug Des Devel Ther       Date:  2014-07-16       Impact factor: 4.162

5.  Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation.

Authors:  Hatice Duman; Ilteris Oguz Topal; Emek Kocaturk; Kubra Cure; Ilknur Mansuroglu
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

6.  Acute Generalized Exanthematous Pustulosis following SARS-CoV-2 Virus: Remdesivir as a Suspected Culprit.

Authors:  Fatemeh Mohaghegh; Parvaneh Hatami; Zeinab Aryanian; Farahnaz Fatemi; Zeinab Mohseni Afshar
Journal:  Case Rep Med       Date:  2022-08-10

Review 7.  Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients.

Authors:  Enriqueta Vallejo-Yagüe; Adrian Martinez-De la Torre; Omar S Mohamad; Shweta Sabu; Andrea M Burden
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.